Seraph Names Fouad Sayegh as Product VP

DETROIT, February 21, 2020 – Seraph Biosciences, Inc., creator of Seraspec®, is pleased to welcome Mr. Fouad Sayegh as its new Vice President of Product Development. Mr. Sayegh brings over 30 years of experience in the development of clinical, veterinary, and agricultural immunodiagnostics. Over the course of his distinguished career, Mr. Sayegh has led numerous technical teams in the successful development and commercialization of over 30 diagnostic tests for various applications including infectious disease, tumor markers, and drugs of abuse.

Prior to joining Seraph, Mr. Sayegh served as Associate Director of Veterinary Diagnostics for Zoetis Inc. Zoetis is the world’s largest producer of medicine and vaccinations for pets and livestock. During his tenure at Zoetis, Mr. Sayegh led the research, development, and
commercialization of point-of-care and instrument-based diagnostic products that detect viruses and bacteria in livestock and companion animals.

Mr. Sayegh also has extensive experience with the design control process, validation, and commercialization of FDA-regulated clinical diagnostic tests. As Director of Research & Development for Chembio Diagnostic Systems, Inc., he oversaw the development and FDA clearance of over five (5) infectious disease assays for the company’s patented Dual Path Platform (DPP®) technology, which supports three (3) multiplex diagnostic tests. Similarly, at Siemens Healthcare, Mr. Sayegh successfully validated and launched 10 automated systems-based immunodiagnostic products resulting in successful FDA clearance and subsequent commercialization. Mr. Sayegh’s experience as a technical leader, researcher, and scientist in the veterinary and human diagnostic space lends itself well to the commercialization of Seraspec® as a point-of-care technology.

Seraph’s Chief Executive Officer, Jim Shanley, is very optimistic about the addition of Mr. Sayegh to the core management team.

“I would like to both thank and congratulate our team in their diligence in identifying a candidate with just the right blend of commercial animal/human health IVD experience”, said Shanley, “Fouad not only demonstrated his expertise early on, but his thoughtful leadership style is proving to be a tremendous asset.”

About Seraph Biosciences, Inc.

Incorporated in 2016, Seraph Biosciences Inc. is a biotechnology company dedicated to commercializing Seraspec® – a fully automated pathogen identification platform capable of delivering near real-time pathogen detection. Based in Detroit, Michigan, Seraph’s mission is to provide disruptive biomedical solutions to front-line providers and their patients at the point of care.